{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-270560","form_type":"8-K","ticker":"RKDA","cik":"0001469443","company_name":"Arcadia Biosciences, Inc.","filed_at":"2026-06-15T15:31:39+00:00","discovered_at":"2026-06-15T15:33:00.537173+00:00","generated_at":"2026-06-15T15:33:13.745943+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Arcadia Biosciences raises $4M via private placement of pre-funded warrants and options","bullets":["Sold 3.88M pre-funded warrants and Series A-1/A-2 options at $1.03 per unit, gross proceeds ~$4M.","Pre-funded warrants exercisable at $0.0001; Series A-2 options at $0.91, immediately exercisable.","Series A-1 options exercisable at $0.91 after stockholder approval, expire five years later.","H.C. Wainwright acted as exclusive placement agent; 7% cash fee plus placement agent warrants.","Net proceeds to be used for working capital and general corporate purposes; offering closed June 12, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-270560","json":"https://secwatch.observer/filing/0001193125-26-270560.json","markdown":"https://secwatch.observer/filing/0001193125-26-270560.md","text":"https://secwatch.observer/filing/0001193125-26-270560.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1469443/000119312526270560/0001193125-26-270560-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1469443/000119312526270560/rkda-20260611.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T15:33:13.745943+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4353151e9fc2cec5e6237f9aad2d7cb7d67e04d4","claim":"Arcadia Biosciences, Inc. entered into Purchase Agreement with an institutional accredited investor valued at approximately $4 million (effective 2026-06-11).","evidence_excerpt":"On June 11, 2026, Arcadia Biosciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional accredited investor (the “Purchaser”) for the sale and issuance in a private placement","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1469443/000119312526270560/0001193125-26-270560-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an institutional accredited investor"},{"label":"Value","value":"approximately $4 million"},{"label":"Effective","value":"2026-06-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}